埃罗妥珠单抗、来那度胺、硼替佐米、地塞米松及自体造血干细胞移植治疗新诊断多发性骨髓瘤(GMMG-HD6):一项随机3期试验结果
GMMG-HD6是一项在德国43个主要试验中心和26个相关中心开展的3期随机试验,纳入564例适合移植的新诊断多发性骨髓瘤患者,随机分配至RVd/R、RVd/E-R、E-RVd/R或E-RVd/E-R四组。中位随访49.8个月后,四组无进展生存期无差异(校正log-rank P=0.86),3年无进展生存率分别为69%、69%、66%和67%。在RVd诱导或巩固及来那度胺维持治疗中加入埃罗妥珠单抗未提供临床获益。
要点
- 四组3年无进展生存率分别为69%、69%、66%和67%,无进展生存期无差异(校正log-rank P=0.86)。
- 感染(3级或更差)是所有治疗组最常见的不良事件,E-RVd/E-R组发生48例(34%)最高。
- 研究期间共有9例治疗相关死亡。
核心结论
- 在适合移植的新诊断多发性骨髓瘤患者中,于RVd诱导或巩固及来那度胺维持治疗中加入埃罗妥珠单抗未提供临床获益。
- 含埃罗妥珠单抗的治疗可能保留用于复发或难治性多发性骨髓瘤患者。
研究设计与样本
- GMMG-HD6是一项在德国43个主要试验中心和26个相关试验中心开展的3期随机试验。
- 纳入年龄18-70岁、既往未经治疗的症状性多发性骨髓瘤患者,WHO体能状态0-3(3分仅允许由骨髓瘤疾病本身而非合并症所致)。
- 患者按1:1:1:1随机分配至四个治疗组:RVd/R、RVd/E-R、E-RVd/R和E-RVd/E-R。
- 诱导治疗为4个21天周期的RVd或E-RVd,随后行自体造血干细胞移植,再行2个21天周期的RVd或埃罗妥珠单抗联合RVd巩固治疗,随后接受来那度胺或来那度胺联合埃罗妥珠单抗维持治疗2年。
- 主要终点为无进展生存期,在改良意向治疗(ITT)人群中分析;安全性在所有接受至少一剂试验药物的患者中分析。
主要发现
- 中位随访49.8个月(IQR 43.7-55.5)后,四组无进展生存期无差异(校正log-rank P=0.86)。
- RVd/R、RVd/E-R、E-RVd/R和E-RVd/E-R组的3年无进展生存率分别为69%(95%CI 61-77)、69%(95%CI 61-76)、66%(95%CI 58-74)和67%(95%CI 59-75)。
- 感染(3级或更差)是所有治疗组中最常见的不良事件:RVd/R组28例(20%,28/137)、RVd/E-R组32例(23%,32/138)、E-RVd/R组35例(25%,35/138)、E-RVd/E-R组48例(34%,48/142)。
- 严重不良事件(3级或更差)发生率:E-RVd/E-R组68例(48%,68/142)、RVd/R组53例(39%,53/137)、RVd/E-R组53例(38%,53/138)、E-RVd/R组50例(36%,50/138)。
- 研究期间共有9例治疗相关死亡:RVd/R组2例(1例脓毒症和1例毒性结肠炎)被认为与来那度胺相关;RVd/E-R组1例脑膜脑炎被认为与来那度胺和埃罗妥珠单抗相关;E-RVd/R组4例(1例肺栓塞、1例感染性休克、1例非典型肺炎和1例心血管衰竭)和E-RVd/E-R组2例(1例脓毒症和1例肺炎及肺纤维化)被认为与来那度胺或埃罗妥珠单抗或两者相关。
临床怎么用
- 作者认为,含埃罗妥珠单抗的治疗可能保留用于复发或难治性多发性骨髓瘤患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The aim of this trial was to investigate the addition of the anti-SLAMF7 monoclonal antibody elotuzumab to lenalidomide, bortezomib, and dexamethasone (RVd) in induction and consolidation therapy as well as to lenalidomide maintenance treatment in transplant-eligible patients with newly diagnosed multiple myeloma. METHODS: GMMG-HD6 was a phase 3, randomised trial conducted at 43 main trial sites and 26 associated trial sites throughout Germany. Adult patients (aged 18-70 years) with previously untreated, symptomatic multiple myeloma, and a WHO performance status of 0-3, with 3 being allowed only if caused by myeloma disease and not by comorbid conditions, were randomly assigned 1:1:1:1 to four treatment groups. Induction therapy consisted of four 21-day cycles of RVd (lenalidomide 25 mg orally on days 1-14; bortezomib 1·3 mg/m2 subcutaneously on days 1, 4, 8, and 11]; and dexamethasone 20 mg orally on days 1, 2, 4, 5, 8, 9, 11, 12, and 15 for cycles 1-2) or, RVd induction plus elotuzumab (10 mg/kg intravenously on days 1, 8, and 15 for cycles 1-2, and on days 1 and 11 for cycles 3-4; E-RVd). Autologous haematopoietic stem-cell transplantation was followed by two 21-day cycles of either RVd consolidation (lenalidomide 25 mg orally on days 1-14; bortezomib 1·3 mg/m2 subcutaneously on days 1, 8, and 15; and dexamethasone 20 mg orally on days 1, 2, 8, 9, 15, and 16) or elotuzumab plus RVd consolidation (with elotuzumab 10 mg/kg intravenously on days 1, 8, and 15) followed by maintenance with either lenalidomide (10 mg orally on days 1-28 for cycles 1-3; thereafter, up to 15 mg orally on days 1-28; RVd/R or E-RVd/R group) or lenalidomide plus elotuzumab (10 mg/kg intravenously on days 1 and 15 for cycles 1-6, and on day 1 for cycles 7-26; RVd/E-R or E-RVd/E-R group) for 2 years. The primary endpoint was progression-free survival analysed in a modified intention-to-treat (ITT) population. Safety was analysed in all patients who received at least one dose of trial medication. This trial is registered with ClinicalTrials.gov, NCT02495922, and is completed. FINDINGS: Between June 29, 2015, and on Sept 11, 2017, 564 patients were included in the trial. The modified ITT population comprised 559 (243 [43%] females and 316 [57%] males) patients and the safety population 555 patients. After a median follow-up of 49·8 months (IQR 43·7-55·5), there was no difference in progression-free survival between the four treatment groups (adjusted log-rank p value, p=0·86), and 3-year progression-free survival rates were 69% (95% CI 61-77), 69% (61-76), 66% (58-74), and 67% (59-75) for patients treated with RVd/R, RVd/E-R, E-RVd/R, and E-RVd/E-R, respectively. Infections (grade 3 or worse) were the most frequently observed adverse event in all treatment groups (28 [20%] of 137 for RVd/R; 32 [23%] of 138 for RVd/E-R; 35 [25%] of 138 for E-RVd/R; and 48 [34%] of 142 for E-RVd/E-R). Serious adverse events (grade 3 or worse) were observed in 68 (48%) of 142 participants in the E-RVd/E-R group, 53 (39%) of 137 in the RVd/R, 53 (38%) of 138 in the RVd/E-R, and 50 (36%) of 138 in the E-RVd/R (36%) group. There were nine treatment-related deaths during the study. Two deaths (one sepsis and one toxic colitis) in the RVd/R group were considered lenalidomide-related. One death in the RVd/E-R group due to meningoencephalitis was considered lenalidomide and elotuzumab-related. Four deaths (one pulmonary embolism, one septic shock, one atypical pneumonia, and one cardiovascular failure) in the E-RVd/R group and two deaths (one sepsis and one pneumonia and pulmonary fibrosis) in the E-RVd/E-R group were considered related to lenalidomide or elotuzumab, or both. INTERPRETATION: Addition of elotuzumab to RVd induction or consolidation and lenalidomide maintenance in patients with transplant-eligible newly diagnosed multiple myeloma did not provide clinical benefit. Elotuzumab-containing therapies might be reserved for patients with relapsed or refractory multiple myeloma. FUNDING: Bristol Myers Squibb/Celgene and Chugai.
引用
- Mai EK, Goldschmid H, Miah K, et al. Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial. Lancet Haematol. 2024. PMID: 38302221. doi:10.1016/S2352-3026(23)00366-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。